RAC-US Exam Dumps Free Test Engine Verified By RAC Regulatory Affairs Certification Certified Experts
Use Real RAPS Achieve the RAC-US Dumps - 100% Exam Passing Guarantee
The RAC-US certification exam is a valuable credential for regulatory affairs professionals working in the United States. It covers a wide range of topics related to US regulations and laws and is recognized as a valuable credential by many companies in the pharmaceutical, medical device, and biotechnology industries.
The RAC-US exam covers a wide range of regulatory topics including preclinical and clinical development, regulatory strategy, post-market surveillance, quality assurance, and compliance. Regulatory Affairs Certification (RAC) US certification is highly regarded in the industry and is a valuable asset for regulatory professionals seeking career advancement opportunities. It demonstrates a commitment to professional development and a high level of regulatory knowledge.
NEW QUESTION # 54
A company is developing a device-drug combination product. Which of the following should be evaluated FIRST in order to determine the applicable guidance documents?
- A. Determination of primary mode of action
- B. Guidance documents for the device
- C. Approved indications of the drug
- D. Determination of product design deliverables
Answer: D
NEW QUESTION # 55
A company is preparing the submission package for a drug to be registered in international markets. When preparing the legal documentation, which document MUST comply with the
WHO recommendations?
- A. Certificate of Pharmaceutical Product
- B. Certificate of Analysis for the finished product
- C. Certificate of GMP
- D. Certificate of Free Sale
Answer: A
NEW QUESTION # 56
A company is developing a new line of products in an area that is new to the company.
What is the BEST approach?
- A. Obtain regulatory documents and history and provide the information to R&D.
- B. Ask the trade association representative to provide an overview of the new product area to the marketing team.
- C. Obtain competitor research and provide the information to the management team.
- D. Summarize regulatory documents and history and provide the information to the management team.
Answer: D
NEW QUESTION # 57
The manufacturer of an API was changed from Company X to Company Y during the late stage of a new drug development. Despite differences in the manufacturing processes of the companies, both APIs meet the current specifications. Which is the MOST appropriate information to include in the final submission documents?
- A. Information deemed appropriate by the regulatory authority
- B. The process information and analytical result of Company Y API
- C. The process information and analytical result of Company X API
- D. The process information and the comparative analytical result of APIs from both companies
Answer: D
NEW QUESTION # 58
During a routine review of promotional materials for a product, a regulatory affairs professional discovers an off-label indication. Which of the following would be the FIRST follow-up action for the regulatory affairs professional to take?
- A. Request that doctors stop using the product for the off-label indication.
- B. Allow doctors to use the product for the off-label indication.
- C. Communicate with the sales department to stop using the promotional materials.
- D. Contact the marketing department to recall the product.
Answer: C
NEW QUESTION # 59
A global company has obtained a patent in a specific country for a newly marketed product.
What would be the BEST advice In order to protect the patent in other countries?
- A. Use the community patent system.
- B. Use the Madrid system.
- C. File design patents in target countries.
- D. File patents of interest in target countries.
Answer: D
NEW QUESTION # 60
As part of the regulatory strategy for companies intending to manufacture a psychotropic product, which of the following approvals should be received FIRST?
- A. Import license
- B. Export license
- C. Product license
- D. Site license
Answer: D
NEW QUESTION # 61
A company is developing a line of products for which no ISO standard of performance is available. As a result, the company wishes to propose developing such a standard. Whom should the company contact in order to start the development of the new standard?
- A. The ISO technical committee in charge of the area
- B. The ISO Secretariat
- C. The ISO national member body
- D. The country's regulatory authority
Answer: C
NEW QUESTION # 62
A drug product presents degradation during the manufacturing process. In addition to the amount, what information should be provided FIRST in order to use API overage?
- A. Formulation
- B. Property
- C. Specification
- D. Justification
Answer: D
NEW QUESTION # 63
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 4
- B. Module 1
- C. Module 3
- D. Module 2
Answer: D
NEW QUESTION # 64
You discover that your company's top selling product in the last two years has been used off-label.
The off-label use is estimated to be about 70%, and it has been consistent since the product was first released to the market. Which of the following is MOST appropriate?
- A. No action is required since it is an off-label use.
- B. File a report to regulatory authorities and advise the marketing department to prevent future off-label use.
- C. Discuss with regulatory authorities to investigate how to have the off-label indication approved.
- D. Advise the senior management to send a "Dear Dr." letter.
Answer: C
NEW QUESTION # 65
Which of the following is NOT required to be included in a marketing application?
- A. Quality, safety, and efficacy Information
- B. Evidence of fee payment
- C. Administrative forms
- D. Final printed label
Answer: B
NEW QUESTION # 66
In addition to protection, what parameters MUST be considered when selecting the primary package (or a product?
- A. Volume and material
- B. Compatibility and safety
- C. Efficacy and material
- D. Safety and efficacy
Answer: B
NEW QUESTION # 67
SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the following?
- A. Causes of non-conformities
- B. Adverse environmental impacts
- C. Late and/or incorrect deliverables
- D. Inadequate training
Answer: A
NEW QUESTION # 68
Which of the following BEST describes the content of the "Physical, Chemical, and
Pharmaceutical Properties and Formulation" section of an IB?
- A. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation method of the finished product
- B. A detailed summary of the physical and chemical properties of the drug product with a signed expert statement addressing the suitability and stability of the formulation for its intended use
- C. A brief summary of relevant physical, chemical, and pharmaceutical properties:
instructions for storage and handling of the dosage form: and a description of the formulation - D. A review of available data to support the determination of the chemical structure and physical attributes of the drug substance plus batch analysis and stability data for the finished formulation
Answer: C
NEW QUESTION # 69
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
- A. Subject's hospitalization is prolonged during the clinical trial.
- B. Subject's hospitalization is due to an unscheduled hip operation.
- C. Subject is hospitalized for the purpose of product administration.
- D. Subject is hospitalized due to complications of the product administration.
Answer: C
NEW QUESTION # 70
A regulation change is imminent and may require further non-clinical testing on a product currently in Phase III clinical trials. What is the most appropriate action to take FIRST?
- A. Arrange for additional testing of the product at the testing facility.
- B. Consult with the company's legal department regarding options.
- C. Obtain a copy of the proposed regulation and analyze the impact.
- D. Inform the company's senior management and arrange an emergency meeting
Answer: C
NEW QUESTION # 71
Which of the following BEST describes the process of post-marketing surveillance for healthcare products?
- A. Systematic procedure to review published scientific journals
- B. Vigilance procedure to notify the regulatory authorities about serious incidents
- C. Vigilance procedure to ensure the full traceability of the products
- D. Systematic procedure to review experiences with the products in use
Answer: C
NEW QUESTION # 72
What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the vendors comply with GMP requirements?
- A. Document and perform audits.
- B. Request documentation from the sub-contractor.
- C. Ask the vendor to take responsibility.
- D. Request an inspection from a regulatory authority.
Answer: A
NEW QUESTION # 73
In preparation for the development of a new line of products, a regulatory affairs professional is asked to prepare a short presentation for senior management. Which of the following topics is MOST important to cover?
- A. Potential clinical sites for the Phase III clinical trial
- B. Previous actions taken by regulatory authorities on similar products
- C. Capacity of the manufacturing facilities to fully produce the new product
- D. Regulatory requirements for labeling and packaging
Answer: B
NEW QUESTION # 74
The safety database for an anti-hypertensive drug consists of the following:
* 461 patients exposed for three months
* 343 patients exposed for six months
* 112 patients exposed for nine months
* 74 patients exposed for 12 months
Overall exposure is 2.000 patients. Which long-term ICH data requirement has NOT been met?
- A. 500 patients for three months
- B. 200 patients for nine months
- C. 3.000 total patient exposures
- D. 100 patients for 12 months
Answer: D
NEW QUESTION # 75
A process is ultimately validated to ensure which of the following?
- A. The process consistently produces the desired results.
- B. The process meets the regulatory requirements.
- C. The process meets the quality system requirements.
- D. The process consistently meets the desired Quantity standards
Answer: A
NEW QUESTION # 76
After submission to the regulatory authority, a substantial error was found in the application. In order to resolve this issue, what should be done FIRST?
- A. Inform upper management immediately.
- B. Resubmit the entire package.
- C. Contact the legal department and ask them how to proceed.
- D. Verify the procedure in the regulation for the corrections.
Answer: D
NEW QUESTION # 77
Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control activities for a medical device?
- A. Quality by design analysis
- B. Failure modes, effects, and criticality analysis
- C. Fishbone analysis
- D. Fault tree analysis
Answer: B
NEW QUESTION # 78
In order to develop a global drug product, what is the MOST important environmental characteristic to consider in the country of intended use?
- A. Product registration
- B. Product formulation
- C. Product requirements
- D. Product stability
Answer: D
NEW QUESTION # 79
......
Check the Free demo of our RAC-US Exam Dumps with 100 Questions: https://freedumps.torrentvalid.com/RAC-US-valid-braindumps-torrent.html